Quell Therapeutics Initiates CHILL Phase 1/2 Trial of Novel QEL-005 CAR-Treg Therapy in Refractory Rheumatoid Arthritis and Systemic Sclerosis Following UK CTA Approval

Core Insights - Quell Therapeutics has initiated a Phase 1/2 clinical study named "CHILL" to evaluate its autologous CAR-Treg therapy, QEL-005, for treating Rheumatoid Arthritis and Systemic Sclerosis, following approval from the UK MHRA [1][2] Company Overview - Quell Therapeutics is a leader in developing engineered T-regulatory (Treg) cell therapies aimed at addressing serious medical conditions driven by the immune system [10] - The company utilizes its proprietary Foxp3 Phenotype Lock™ technology to create Treg cell therapies with enhanced persistence, potency, and stability compared to earlier generations [11] Product Details - QEL-005 is based on Quell's Phenotype Locked™ CAR-Treg platform, designed to selectively activate and exert immune suppression in inflamed tissues, providing broad control over disease activity [3] - The therapy employs a Treg-optimized CD19-directed CAR, which activates in the presence of B cells, facilitating immune regulation through bystander suppression [3] Clinical Study Insights - The CHILL study will recruit up to 16 adult participants across the UK, Germany, and Spain, with patient enrollment currently underway [2] - Early clinical findings from the study are anticipated in Q1 2027 [2] Pre-Clinical Findings - Pre-clinical studies presented at the ACR Convergence 2025 demonstrated QEL-005's immunomodulatory activity across various immune cell types involved in autoimmune inflammation, distinguishing it from traditional CAR-T and B-cell depletion therapies [4] - The findings suggest that QEL-005 may offer a safer and better-tolerated option with broader efficacy in complex autoimmune diseases [4] Additional Clinical Insights - Results from Quell's LIBERATE Phase 1/2 trial in liver transplantation indicate the clinical safety and functional stability of Quell's CAR-Treg cells for over one year [5] - The therapy shows evidence of trafficking and engraftment within target tissues, suggesting its potential effectiveness in autoimmune conditions [5] Expert Commentary - The CEO of Quell highlighted the significance of the CHILL study as a milestone, emphasizing the differentiated therapeutic approach of QEL-005 to restore immune balance rather than solely depleting B cells [6] - Experts involved in the study expressed optimism about the potential of CAR-Tregs to achieve durable disease control and possibly a cure for patients with autoimmune diseases [6][9]